SG11201907199QA - Cancer treatment - Google Patents
Cancer treatmentInfo
- Publication number
- SG11201907199QA SG11201907199QA SG11201907199QA SG11201907199QA SG11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- janssen
- turnhoutseweg
- beerse
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Laminated Bodies (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/498 (2006.01) A61P 35/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). G01N 33/574 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/EP2018/052694 Published: — with international search report (Art. 21(3)) 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/455211 06 February 2017 (06.02.2017) US 17209098.7 20 December 2017 (20.12.2017) EP (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE). (72) Inventors: STUYCKENS, Kim; c/o Janssen Pharmaceu- tica NV, Turnhoutseweg 30, 2340 Beerse (BE). PEREZ RUIXO, Juan, Jose; c/o Janssen-Cilag, S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas,5-7, 5° planta, Campo de las Naciones, 28042 Madrid (ES). DE PORRE, Peter, Marie, Z.; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). AVADHANI, An- jali, Narayan; c/o Janssen Pharmaceuticals Inc., Spring- house Campus, 1400 McKean Road, Springhouse, Pen- syllvania 19477 (US). LORIOT, Yohann; c/o Gustave Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif Cedex (FR). SIEFKER-RADTKE, Arlene, O.; c/o Janssen Phar- maceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). (74) Agent: VERVOORT, Liesbeth; Turnhoutseweg 30, 2340 Beerse (BE). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: CANCER TREATMENT (57) : The present invention provides a method for the treatment of cancer with erdafitinib. o mons °nolo DID mimiciolol Imo oimIE (10) International Publication Number WO 2018/141921 Al W O 20 18/ 1419 21 Al
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455211P | 2017-02-06 | 2017-02-06 | |
| EP17209098 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907199QA true SG11201907199QA (en) | 2019-09-27 |
Family
ID=61094531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907199QA SG11201907199QA (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
| SG10202105110VA SG10202105110VA (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202105110VA SG10202105110VA (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11077106B2 (en) |
| EP (2) | EP4286005A3 (en) |
| JP (2) | JP2020505425A (en) |
| KR (1) | KR20190110581A (en) |
| CN (1) | CN110198716A (en) |
| AU (2) | AU2018216969B2 (en) |
| BR (1) | BR112019016043A2 (en) |
| CA (1) | CA3049737A1 (en) |
| DK (1) | DK3576740T3 (en) |
| ES (1) | ES2953005T3 (en) |
| FI (1) | FI3576740T3 (en) |
| HR (1) | HRP20230697T1 (en) |
| HU (1) | HUE062453T2 (en) |
| IL (1) | IL268463A (en) |
| JO (1) | JOP20190190A1 (en) |
| LT (1) | LT3576740T (en) |
| MX (2) | MX2019009304A (en) |
| PH (1) | PH12019501885A1 (en) |
| PL (1) | PL3576740T3 (en) |
| RS (1) | RS64778B1 (en) |
| SG (2) | SG11201907199QA (en) |
| SI (1) | SI3576740T1 (en) |
| TW (1) | TW202402290A (en) |
| UA (1) | UA126336C2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| HUE058219T2 (en) | 2014-09-26 | 2022-07-28 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| JOP20190190A1 (en) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | Cancer treatment |
| JOP20210266A1 (en) * | 2019-03-29 | 2023-01-30 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| WO2021201201A1 (en) * | 2020-04-03 | 2021-10-07 | インタープロテイン株式会社 | Prophylactic or therapeutic agent for new coronavirus infection (covid-19) and pharmaceutical composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (en) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JOP20190190A1 (en) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | Cancer treatment |
-
2017
- 2017-06-16 JO JOP/2019/0190A patent/JOP20190190A1/en unknown
-
2018
- 2018-02-02 ES ES18702299T patent/ES2953005T3/en active Active
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/en not_active Withdrawn
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/en active
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/en active Pending
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 UA UAA201909567A patent/UA126336C2/en unknown
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/en unknown
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/en unknown
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/en unknown
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/en not_active Application Discontinuation
- 2018-02-02 SI SI201830961T patent/SI3576740T1/en unknown
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/en active
- 2018-02-02 TW TW112109467A patent/TW202402290A/en unknown
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/en unknown
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/en unknown
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/en unknown
- 2018-02-02 RS RS20230615A patent/RS64778B1/en unknown
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
-
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/en unknown
-
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en active Pending
-
2022
- 2022-11-28 JP JP2022189239A patent/JP2023022190A/en active Pending
-
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907199QA (en) | Cancer treatment | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |